Einfluss präoperativer Behandlung auf die Angiogenese und Mikrogefäßdichte bei der Autoimmunhyperthyreose vom Typ Basedow

Zusammenfassung Die Behandlung von Morbus Basedow Patienten mit hohen Joddosen vor Strumektomie, die so genannte Plummerung, führt zu einer deutlichen Reduktion der Blutungskomplikationen. In dieser Studie soll untersucht werden, ob dieser Effekt der Plummerung auf eine Reduktion der Mikrogefä...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: El Djabri, Haisam
Beteiligte: Hassan, Iyad (Prof. Dr. med.) (BetreuerIn (Doktorarbeit))
Format: Dissertation
Sprache:Deutsch
Veröffentlicht: Philipps-Universität Marburg 2010
Operative Medizin
Schlagworte:
Online Zugang:PDF-Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

1. Macchiarelli G: Thyroxine treatment stimulated ovarian follicular angiogenesis in immature hypothyroid rats. Histol Histopathol. 2008;23:1387-89.


2. Dumont JE, Lamy F, Roger P, Maenhaut C: Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiol Rev. 1992;72:667-97.


3. Meng W: Carl Adolph von Basedow -on the 200 th anniversary of his birth. Z Ärztl Fortbild Qualitätssich. 1999;93:5-10.


4. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease.


5. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.


6. Ye C, Feng C, Wang S, Liu X, Lin Y, Li M: Antiangiogenic and antitumor effects of endostatin on follicular thyroid carcinoma. Endocrinology 2002;143:3522-8.


7. Wollman SH, Herveg JP, Zeligs JD, Ericson LE: Blood capillary enlargement during the development of thyroid hyperplasia in the rat. Endocrinology 1978;103:2306-14.


8. Patel VA, Hill DJ, Eggo MC, Sheppard MC, Becks GP, Logan A: Changes in the immunohistochemical localisation of fibroblast growth factor-2, transforming growth factor-ß 1 and thrombospondin-1 are associated with early angiogenic events in the hyperplastic rat thyroid. J Endocrinol. 1996;148:485-99.


9. Ramsden JD: Commentary: Angiogenesis in the thyroid gland. J Endocrinol. 2000;166:475-80.


10. Tseleni-Balafouta S, Kavantzas N, Balafoutas D, Patsouris E: Comparative Study of Angiogenesis in Thyroid Glands with Graves Disease and Hashimoto's Thyreoiditis. Appl Immunohistochem Mol Morphol. 2006;14:203-7.


11. Rangaswamy M, Padhy AK, Gopinath PG, Shukla NK, Gupta K, Kapoor MM: Effect of Lugol's iodine on the vascularity of the thyroid gland in hyperthyroidism. Nucl Med Commun. 1989;10:679-84.


12. Velten M: Effect of preoperative administration of Lugol's Solution on thyroid blood flow in hyperthyroidism. Ann Chir. 1998;52:229-33.


13. Schoenberger J, Grimm D, Kossmehl P, Infanger M, Kurth E, Eilles C: Effects of PTK787/ ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study. Endocrinology 2004;145:1031-8.


14. Denef JF, Ovaert C, Many MC: Experimental goitrogenesis. Ann Endocrinol (Paris) 1989;50:1-15.


15. Nagura S, Katoh R, Miyagi E, Shibuya M, Kawaoi A: Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor-1 (flt-1) in Graves Disease possibly correlated with increased Vascular Density. Hum Pathol. 2001;32:10-7.


16. Suzuki K, Mori A, Saito J, Moriyama E, Ullianich L, Kohn LD: Follicular thyroglobulin suppresses iodide uptake by suppressing expression of the sodium/iodine symporter gene. Endocrinology 1999;140:5422-30.


17. Schumm-Draeger PM: Hyperthyreose Typ Basedow – Gibt es einen therapeutischen Standard? Konservative Therapie. Zentralbl. Chir. 1997;122: 224-26.


18. Iitaka M, Miura S, Yamanaka K, Kawasaki S, Kitahama S, Kawakami Y, Kakinuma S, Oosuga I, Wada S, Katayama S: Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves disease and Hashimoto's thyroiditis. J Clin Endocrinol Metab. 1998;83:3908-12.


19. Bühling KJ, Lepenies J, Witt K. Intensivkurs: Allgemeine und spezielle Pathologie. Urban & Schwarzenberg. 1. Auflage. 1995.


20. Yamada E, Yamazaki K, Takano K, Obara T, Sato K: Iodide inhibits Vascular Endothelial Growth Factor-A Expression in Cultured Human Thyroid Follicles: A Microarray Search for Effects of Thyrotropin and Iodide on Angiogenesis Factors. Thyroid 2006;16:545-54.


21. Nawroth PP, Ziegler R: Klinische Endokrinologie und Stoffwechsel. Springer Verlag. 2001.


22. Carmeliet P, Collen D: Molecular analysis of blood vessel formation and disease. Am J Physiol. 1997;273:2091-104.


23. Ferrara N, Houck K, Jakeman L, Leung DW: Molecular and biological properties of the vascular endothelial growth factor family proteins. Endocr Rev. 1992;13:18-32.


24. Perros P, Kendall-Taylor P: Natural History of Thyroid Eye Disease. Thyroid 1998;8:423-5.


25. Dralle H, Schober O, Hesch RD: Operatives Therapiekonzept der Immun- thyreopathie. Langenbecks Arch Chir. 1987;371:217-32.


26. Wang JF, Milosveski V, Schramek C, Fong GH, Becks GP, Hill DJ: Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function. J Endocrinol. 1998;157:5-12.


27. Sim BK, O'Reilly MS, Liang H, Fortier AH, He W, Madsen JW, Lapcevich R, Nacy CA: Recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res. 1997;57:1329-34.


28. Plummer HS: Results of administering iodin to patients having exophthalmic goiter. JAMA 1923;80:1955.


29. Röher HD: Morbus Basedow: Chirurgische Behandlung. Langenbecks Arch.


30. Krassas GE, Tziomalos K, Pontikides N, Lewy H, Laron Z: Seasonality of month of birth of patients with Graves' and Hashimoto's diseases differ from that in the general population. Eur J Endocrinol. 2007;156:631-6.


31. Kucharz EJ, Kotulska A, Kopeć M, Stawiarska-Pieta B, Pieczyrak R: Serum level of the circulating inhibitor endostatin in patients with hyperthyroidism or hypothyroidism. Wien Klin Wochenschr. 2003;115:179-81.


32. Selwyn T: Sir Thomas Peel Dunhill (1876-1957). World J. Surg. 1997;660-62.


33. Yamaguchi S, Shibuya M: Stimulation by thyroid-stimulating hormone and Graves' Immunglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA in the rat thyroid in vivo. J Clin Invest. 1995;96:1295-302.


34. Puls T: The changing aspect of thyroid surgery: A review of 130 consecutive cases. Acta Otorhinolaryngol Belg. 1993;47:351-4.


35. Chang DC, Wheeler MH, Woodcock JP, Curley I, Lazarus JR, Fung H, John R, Hall R, McGregor AM: The effect of preoperative Lugol's iodine in thyroid blood flow in patients with Graves`hyperthyroidism. Surgery 1987;102:1055-61.


36. Plummer HS, Boothby MB: The value of iodin in exophthalmic goiter. In Collected papers of the Mayo Clinic and the Mayo Foundation 1923: 565-76.


37. Soh EY, Sobhi SA, Wong MG, Meng YG, Siperstein AE, Clark OH, Duh QY: Thyroid-stimulating hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines. Surgery 1996;120:944-7.


38. Mak WW, Eggo MC, Burrow GN: Thyrotropin regulation of plasminogen actiator activity in primary cultures of ovine thyroid cells. Biochem Biophys Res Commun. 1984;123:633-40.


39. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-86.


40. Viglietto G, Maglione D, Rambaldi M, Cerutti J, Romano A, Trapasso F, Fedele M, Ippolito P, Chiappetta G, Botti G: Upregulation of vascular endothelial growth factor (VEGF) and down-regulation of placenta growth factor (PIGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 1995;11:1569-79.


41. Jebreel A, England J, Bedford K, Murphy J, Karsai L, Atkin S: Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid disorders. Int J Exp Pathol. 2007;88:271-7.


42. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular epithelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9.


43. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT: Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246:1309-12.


44. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG: Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA. 1991;88:9267-71.